- $869.21bn
- $892.92bn
- $34.12bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 53.9 | ||
| PEG Ratio (f) | 1.94 | ||
| EPS Growth (f) | 38.57% | ||
| Dividend Yield (f) | 0.64% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 65.57 | ||
| Price to Tang. Book | 756.52 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 23.38 | ||
| EV to EBITDA | 95.56 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.48% | ||
| Return on Equity | 51.15% | ||
| Operating Margin | 20.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 22,319.5 | 24,539.8 | 28,318.4 | 28,541.4 | 34,124.1 | 43,055.18 | 53,111.41 | 9.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +6.15 | +33.92 | +2.16 | +4.57 | +23.45 | +36.79 | +40 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.
Directors
- David Ricks CHM (53)
- Anat Ashkenazi CFO (48)
- Aarti Shah SVP (56)
- Daniel Skovronsky SVP (47)
- Melissa Barnes SVP (53)
- Anat Hakim SVP (51)
- Stephen Fry SVP (55)
- Patrik Jonsson SVP (54)
- Michael Mason SVP (54)
- Johna Norton SVP (54)
- Myles O'Neill SVP (62)
- Leigh Pusey SVP (58)
- Anne White SVP (52)
- Ilya Yuffa SVP (46)
- Juan Luciano LED (59)
- Raul Alvarez IND (66)
- Katherine Baicker IND (49)
- Michael Eskew IND (71)
- J. Erik Fyrwald IND (61)
- Jamere Jackson IND (52)
- Kimberly Johnson IND (48)
- William Kaelin IND (63)
- Marschall Runge IND (66)
- Gabrielle Sulzberger IND (61)
- Jackson Tai IND (71)
- Karen Walker IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 17th, 1901
- Public Since
- July 9th, 1970
- No. of Shareholders
- 18,871
- No. of Employees
- 43,000
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 950,405,386
- Address
- Lilly Corporate Ctr, INDIANAPOLIS, 46285-0001
- Web
- https://www.lilly.com/
- Phone
- +1 3172762000
- Auditors
- Ernst & Young LLP
Latest News for LLY
Upcoming Events for LLY
Q2 2024 Eli Lilly and Co Earnings Release
Q2 2024 Eli Lilly and Co Earnings Call
Q3 2024 Eli Lilly and Co Earnings Release
Q3 2024 Eli Lilly and Co Earnings Call
Similar to LLY
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
FAQ
As of Today at 20:26 UTC, shares in Eli Lilly and Co are trading at $883.88. This share price information is delayed by 15 minutes.
Shares in Eli Lilly and Co last closed at $883.88 and the price had moved by +93.12% over the past 365 days. In terms of relative price strength the Eli Lilly and Co share price has outperformed the S&P500 Index by +53.67% over the past year.
The overall consensus recommendation for Eli Lilly and Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Eli Lilly and Co dividend yield is 0.53% based on the trailing twelve month period.
Last year, Eli Lilly and Co paid a total dividend of $4.69, and it currently has a trailing dividend yield of 0.53%. We do not have any data on when Eli Lilly and Co is to next pay dividends.
We do not have data on when Eli Lilly and Co is to next pay dividends. The historic dividend yield on Eli Lilly and Co shares is currently 0.53%.
To buy shares in Eli Lilly and Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $883.88, shares in Eli Lilly and Co had a market capitalisation of $840.04bn.
Here are the trading details for Eli Lilly and Co:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: LLY
Based on an overall assessment of its quality, value and momentum Eli Lilly and Co is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Eli Lilly and Co is $863.79. That is 2.27% below the last closing price of $883.88.
Analysts covering Eli Lilly and Co currently have a consensus Earnings Per Share (EPS) forecast of $13.77 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eli Lilly and Co. Over the past six months, its share price has outperformed the S&P500 Index by +35.4%.
As of the last closing price of $883.88, shares in Eli Lilly and Co were trading +29.7% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Eli Lilly and Co PE ratio based on its reported earnings over the past 12 months is 53.9. The shares last closed at $883.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Eli Lilly and Co's management team is headed by:
- David Ricks - CHM
- Anat Ashkenazi - CFO
- Aarti Shah - SVP
- Daniel Skovronsky - SVP
- Melissa Barnes - SVP
- Anat Hakim - SVP
- Stephen Fry - SVP
- Patrik Jonsson - SVP
- Michael Mason - SVP
- Johna Norton - SVP
- Myles O'Neill - SVP
- Leigh Pusey - SVP
- Anne White - SVP
- Ilya Yuffa - SVP
- Juan Luciano - LED
- Raul Alvarez - IND
- Katherine Baicker - IND
- Michael Eskew - IND
- J. Erik Fyrwald - IND
- Jamere Jackson - IND
- Kimberly Johnson - IND
- William Kaelin - IND
- Marschall Runge - IND
- Gabrielle Sulzberger - IND
- Jackson Tai - IND
- Karen Walker - IND